File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy

TitleHistology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy
Authors
KeywordsNSCLC
Histology
Stereotactic body radiation therapy
Stereotactic ablative radiotherapy
Issue Date2018
Citation
Journal of Thoracic Oncology, 2018, v. 13, n. 10, p. 1549-1559 How to Cite?
Abstract© 2018 International Association for the Study of Lung Cancer Introduction: It remains unclear if histology should be independently considered when choosing stereotactic ablative body radiotherapy dose prescriptions for NSCLC. Methods: The study population included 508 patients with 561 lesions between 2000 and 2016, of which 442 patients with 482 lesions had complete dosimetric information. Eligible patients had histologically or clinically diagnosed early-stage NSCLC and were treated with 3 to 5 fractions. The primary endpoint was in-field tumor control censored by either death or progression. Involved lobe control was also assessed. Results: At 6.7 years median follow-up, 3-year in-field control, involved lobe control, overall survival, and progression-free survival rates were 88.1%, 80.0%, 49.4%, and 37.2%, respectively. Gross tumor volume (GTV) (hazard ratio [HR] = 1.01 per mL, p = 0.0044) and histology (p = 0.0225) were independently associated with involved lobe failure. GTV (HR = 1.013, p = 0.001) and GTV dose (cutoff of 110 Gy, biologically effective dose with α/β = 10 [BED10], HR = 2.380, p = 0.0084) were independently associated with in-field failure. For squamous cell carcinomas, lower prescription doses were associated with worse in-field control (12 Gy × 4 or 10 Gy × 5 versus 18 Gy or 20 Gy × 3: HR = 3.530, p = 0.0447, confirmed by propensity score matching) and was independent of GTV (HR = 1.014 per mL, 95% confidence interval: 1.005–1.022, p = 0.0012). For adenocarcinomas, there were no differences in in-field control observed using the above dose groupings (p = 0.12 and p = 0.31, respectively). Conclusions: In the absence of level I data, GTV and histology should be considered to personalize radiation dose for stereotactic ablative body radiotherapy. We suggest lower prescription doses (i.e., 12 Gy × 4 or 10 G × 5) should be avoided for squamous cell carcinomas if normal tissue tolerances are met.
Persistent Identifierhttp://hdl.handle.net/10722/267101
ISSN
2017 Impact Factor: 10.34
2015 SCImago Journal Rankings: 2.597
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShiue, Kevin-
dc.contributor.authorCerra-Franco, Alberto-
dc.contributor.authorShapiro, Ronald-
dc.contributor.authorEstabrook, Neil-
dc.contributor.authorMannina, Edward M.-
dc.contributor.authorDeig, Christopher R.-
dc.contributor.authorAlthouse, Sandra-
dc.contributor.authorLiu, Sheng-
dc.contributor.authorWan, Jun-
dc.contributor.authorZang, Yong-
dc.contributor.authorAgrawal, Namita-
dc.contributor.authorIoannides, Pericles-
dc.contributor.authorLiu, Yongmei-
dc.contributor.authorZhang, Chen-
dc.contributor.authorDesRosiers, Colleen-
dc.contributor.authorBartlett, Greg-
dc.contributor.authorEwing, Marvene-
dc.contributor.authorLanger, Mark P.-
dc.contributor.authorWatson, Gordon-
dc.contributor.authorZellars, Richard-
dc.contributor.authorKong, Feng Ming-
dc.contributor.authorLautenschlaeger, Tim-
dc.date.accessioned2019-01-31T07:20:31Z-
dc.date.available2019-01-31T07:20:31Z-
dc.date.issued2018-
dc.identifier.citationJournal of Thoracic Oncology, 2018, v. 13, n. 10, p. 1549-1559-
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/267101-
dc.description.abstract© 2018 International Association for the Study of Lung Cancer Introduction: It remains unclear if histology should be independently considered when choosing stereotactic ablative body radiotherapy dose prescriptions for NSCLC. Methods: The study population included 508 patients with 561 lesions between 2000 and 2016, of which 442 patients with 482 lesions had complete dosimetric information. Eligible patients had histologically or clinically diagnosed early-stage NSCLC and were treated with 3 to 5 fractions. The primary endpoint was in-field tumor control censored by either death or progression. Involved lobe control was also assessed. Results: At 6.7 years median follow-up, 3-year in-field control, involved lobe control, overall survival, and progression-free survival rates were 88.1%, 80.0%, 49.4%, and 37.2%, respectively. Gross tumor volume (GTV) (hazard ratio [HR] = 1.01 per mL, p = 0.0044) and histology (p = 0.0225) were independently associated with involved lobe failure. GTV (HR = 1.013, p = 0.001) and GTV dose (cutoff of 110 Gy, biologically effective dose with α/β = 10 [BED10], HR = 2.380, p = 0.0084) were independently associated with in-field failure. For squamous cell carcinomas, lower prescription doses were associated with worse in-field control (12 Gy × 4 or 10 Gy × 5 versus 18 Gy or 20 Gy × 3: HR = 3.530, p = 0.0447, confirmed by propensity score matching) and was independent of GTV (HR = 1.014 per mL, 95% confidence interval: 1.005–1.022, p = 0.0012). For adenocarcinomas, there were no differences in in-field control observed using the above dose groupings (p = 0.12 and p = 0.31, respectively). Conclusions: In the absence of level I data, GTV and histology should be considered to personalize radiation dose for stereotactic ablative body radiotherapy. We suggest lower prescription doses (i.e., 12 Gy × 4 or 10 G × 5) should be avoided for squamous cell carcinomas if normal tissue tolerances are met.-
dc.languageeng-
dc.relation.ispartofJournal of Thoracic Oncology-
dc.subjectNSCLC-
dc.subjectHistology-
dc.subjectStereotactic body radiation therapy-
dc.subjectStereotactic ablative radiotherapy-
dc.titleHistology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jtho.2018.06.007-
dc.identifier.scopuseid_2-s2.0-85051050067-
dc.identifier.volume13-
dc.identifier.issue10-
dc.identifier.spage1549-
dc.identifier.epage1559-
dc.identifier.eissn1556-1380-
dc.identifier.isiWOS:000445154800024-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats